GlassScriptPhysician profile
Thomas I Knox
NPI 1609838218
$8,090.83
in general payments reported to CMS, 2019-2025
30 companies · $923 in 2025
The $923 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $844 · 2021: $1,117 · 2022: $1,202 · 2023: $1,275 · 2024: $1,552 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,678 · Education: $72.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,677.75 |
| Education | $72.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,391.17 | 2019-2023 | Xarelto |
| Pfizer INC. | $934.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $846.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $818.37 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $698.20 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $657.95 | 2019-2024 | Farxiga |
| Amgen INC. | $482.51 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.30 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $291.22 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $222.85 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $191.34 | 2023-2024 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $160.38 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $157.69 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $129.29 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.71 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $104.37 | 2019-2022 | |
| Cardiva Medical, INC. | $104.01 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Edwards Lifesciences Corporation | $91.62 | 2024 | |
| Lilly USA, LLC | $63.21 | 2025 | Zepbound, Mounjaro |
| Jazz Pharmaceuticals INC. | $43.26 | 2025 | |
| Cvrx, INC. | $38.11 | 2023 | Barostim Neo System |
| Heartflow, INC. | $29.50 | 2022 | |
| Boston Scientific Corporation | $28.66 | 2024 | Watchman Access System |
| Glaxosmithkline, LLC. | $25.04 | 2025 | Arexvy, Shingrix |
| Medicomp INC | $25.00 | 2021 | |
| Esperion Therapeutics, INC. | $23.66 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.78 | 2020 | |
| Baxter Healthcare | $20.14 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Vivaquant INC, Dba Rhythm Express | $16.45 | 2025 | Rhythm Express |
| Allergan, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.